About Gene Medicin
Gene Medicin is a Healthcare company based in Seoul (South Korea) founded in 2008. Anti-cancer gene medicines are developed for melanoma and lung cancers. Its chief executive, as recorded, is Chae Ok Yun. Gene Medicin offers products and services including GM101, GM102, GM103, GM104, and CDMO/CMO Services. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity in India is (μ£Ό)μ§λ©λμ (U99999MH1977PLC010754).
Company details
Gene Medicin was established in 2008 in Seoul, South Korea, within the biotechnology sector. Anti-cancer gene therapies are developed through a pipeline that includes GM101, which targets malignant melanoma for therapeutic effects; GM102, which addresses proliferation and metastasis in various cancer cells; and GM103, focused on lung cancer inhibition. Technology patents are maintained by the company, with operations centered on gene-based treatments.
- Headquarters Seoul, South Korea
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website gene-medicine.com
- Legal Name (주)진메디신
- Date of Incorporation 10 Aug, 1977
- Jurisdiction Maharashtra, India
Associated legal entities of Gene Medicin
Gene Medicin operates through , (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| , CIN U99999MH1977PLC010754 | Active | 10 Aug 1977 | Nanded, Maharashtra | View details |
Products & Services of Gene Medicin
Gene Medicin offers a comprehensive portfolio of products and services, including GM101, GM102, GM103, GM104, and CDMO/CMO Services.
Therapeutic virus targeting specific cancer cells
Advanced virus for cancer treatment applications
Virus variant in development for oncology use
Pipeline product for targeted cancer therapies
Contract development and manufacturing for biotech partners
People of Gene Medicin
6 people are tracked at Gene Medicin (5 in leadership, 1 in board & advisors).
| Name | Role | Group |
|---|---|---|
Chae Ok Yun | CEO | Leadership |
Eunho Lee | Executive Director | Leadership |
Wonki Bae | Executive Director | Leadership |
중언 안 | Director Process Development | Leadership |
Kyoung Ryun Park | Team Leader/deputy Director Of Clinical Development Team | Leadership |
Chu Yeon-Seong | Advisor | Board & advisors |
Complete people profiles for Gene Medicin
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Web traffic of Gene Medicin
The website of Gene Medicin (gene-medicine.com) receives about 1.2K visits a month.
- Monthly visits1.2K
▼ 40.3% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Gene Medicin
Complete news archive for Gene Medicin
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Gene Medicin
Gene Medicin was founded in 2008.
Gene Medicin is headquartered in Seoul, South Korea.
Chae Ok Yun is the CEO of Gene Medicin, as recorded in our data.
Gene Medicin was established in 2008 in Seoul, South Korea, within the biotechnology sector. Anti-cancer gene therapies are developed through a pipeline that includes GM101, which targets malignant melanoma for therapeutic effects; GM102, which addresses proliferation and metastasis in various cancer cells; and GM103, focused on lung cancer inhibition. Technology patents are maintained by the company, with operations centered on gene-based treatments.
Gene Medicin offers GM101, GM102, GM103, GM104, and CDMO/CMO Services.
Gene Medicin operates through ,.